Allopurinol versus febuxostat for gout

James R O'Dell,Mary T Brophy,Michael H Pillinger,Tuhina Neogi,Paul M Palevsky, Hongsheng Wu,Anne Davis-Karim,Jeff A Newcomb,Ryan Ferguson,David Pittman,Grant W Cannon,Thomas Taylor,Robert Terkeltaub,Amy C Cannella,Bryant R England,Lindsay N Helget,Ted R Mikuls

LANCET RHEUMATOLOGY（2022）

引用 16|浏览14

暂无评分

摘要

Allopurinol and febuxostat achieved serum urate goals in patients with gout; allopurinol was noninferior to febuxostat in controlling flares. Similar outcomes were noted in participants with stage 3 chronic kidney disease. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; ClinicalTrials.gov identifier, NCT02579096.).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要